Pfenex Expects To Be Alone With Teriparatide

Not Expecting Teva Entry Until Later Next Year

Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.

Puzzle_Optimism
Pfenex believes it could get a significant head start with its rival to Lilly's Forteo teriparatide brand in the US • Source: Shutterstock

Pfenex believes it and commercial partner Alvogen could benefit from an extended period as the only direct competition to Eli Lilly’s Forteo (teriparatide) osteoporosis blockbuster in the US. However, Alvogen has not yet launched the hybrid 505(b)(2) drug as the partners are waiting for the US Food and Drug Administration to decide whether to designate the PF708 candidate, which the agency approved in early October under the Bonsity brand name, as therapeutically equivalent, or ‘A-rated’, to Forteo.

Informing investors that he expected Alvogen to launch Bonsity upon receiving the agency’s therapeutic equivalence decision, Pfenex’ CEO Eef Schimmelpennink...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin